Streetbeat News

Stock Prices

DE

A large bearish position has been taken on Deere (NYSE:DE), with 29 uncommon options trades spotted, the majority of which are puts. The sentiment of these big-money traders is split between 41% bullish and 58% bearish. The price of DE is currently down -2.75% at $400.4. Analysts from Oppenheimer, Deutsche Bank, JP Morgan, Stifel, and Credit Suisse have maintained their ratings on Deere, with price targets ranging from $380 to $551.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 6:45 pm

IDEX

Ideanomics Inc's (NASDAQ:IDEX) shares have fallen by 9.7% to $2.10 following the company's recent 1-for-125 reverse stock split. The split was initiated to meet the minimum bid price requirement of $1.00 for maintaining listing on The Nasdaq Capital Market. Over the past month, Ideanomics shares have decreased by approximately 74%.

Portfolio Pulse from Henry Khederian

September 08, 2023 | 6:45 pm

CHPT

RBC Capital Markets analyst Chris Dendrinos initiated coverage on ChargePoint Holdings Inc (NYSE:CHPT) with an Outperform rating and a price target of $9. Dendrinos sees CHPT as the market leader in level 2 charging solutions in the U.S. with a 45% market share. The analyst is bullish on CHPT's strategy and believes it is well positioned to capitalize on the opportunity from EV adoption rates and charging infrastructure demand. CHPT shares are trading lower by 8.5% at $5.76.

Portfolio Pulse from Lekha Gupta

September 08, 2023 | 6:37 pm

BAC

GILD

Shares of Gilead Sciences, Inc (NASDAQ:GILD) are trading higher, bolstered by Bank of America Securities' bullish outlook on the stock. The bank highlighted growth avenues within Gilead's core HIV segment and ventures into hematology/oncology. Analyst Geoff Meacham upgraded the stock from Neutral to Buy, raising the price target from $88 to $95. He identified Gilead's HIV endeavors, especially its next-generation asset, Lenacapavir, as a key growth driver. The bank also noted optimistic moves in hematology and oncology, powered by drugs like Trodelvy and Kite.

Portfolio Pulse from AJ Fabino

September 08, 2023 | 6:31 pm

LCID

TSLA

RBC Capital Markets analyst Tom Narayan initiated coverage on Lucid Group Inc (LCID) with a Sector Perform rating and a price target of $6. Despite Lucid's technology being more efficient than Tesla (TSLA) and other OEMs, the analyst notes low brand awareness and modest demand acceleration. Lucid's strategic partnership with Aston Martin is seen as a potential for future licensing deals. The analyst estimates revenue and adjusted EBITDA loss for FY23, FY24, and FY25.

Portfolio Pulse from Lekha Gupta

September 08, 2023 | 6:31 pm

SCHW

A significant investor has taken a bearish stance on Charles Schwab (NYSE:SCHW), with 56% of recent trades being bearish and 43% bullish. The total amount for put options is $631,806 and for call options is $266,866. The targeted price range for Charles Schwab over the last 3 months is from $40.0 to $65.0. The current price of SCHW is up 1.49% at $58.68, and the next earnings are expected in 38 days.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 6:31 pm

BA

A significant bearish stance on Boeing (NYSE:BA) has been observed in recent unusual options activity. The sentiment among big-money traders is split between 46% bullish and 53% bearish. The whales have been targeting a price range from $100.0 to $260.0 for Boeing over the last 3 months. TD Cowen has maintained their Outperform rating on Boeing, with a price target of $260.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 6:30 pm

SAM

Wedbush analyst Gerald Pascarelli has reiterated a Neutral rating on Boston Beer Company Inc (SAM) and raised the price target from $350 to $370. The analyst believes that the company could deliver shipments or depletions above the midpoint of guidance, resulting in about 100 basis points of upside relative to current street estimates. The raised price target reflects the belief that the multiple has support coming off a strong 2Q. However, the next few months will be crucial for SAM as it will provide better insight into whether increases in investment spend will have a sustained impact on performance.

Portfolio Pulse from Shivani Kumaresan

September 08, 2023 | 6:24 pm

PL

Benchmark analyst Josh Sullivan has reiterated a Buy rating on Planet Labs PBC (NYSE:PL) but lowered the price target from $6.5 to $5. This comes after PL reported 2QFY24 revenues of $53.8 million, slightly below the Street’s $54.1 million. FY24 revenue guidance was also reduced due to extended defense sales cycles. Despite a 13.3% drop in share price, the analyst believes PL is in a position to control costs and consolidate attractive but financially stressed assets.

Portfolio Pulse from Shivani Kumaresan

September 08, 2023 | 6:20 pm

OHI

Mizuho Securities has upgraded Omega Healthcare Investors Inc (OHI) from Neutral to Buy with a price target of $35, up from $31. The upgrade is based on optimistic industry and company-specific factors, including higher hospital admissions, a favorable regulatory environment, and portfolio de-risking. Despite ongoing labor challenges, senior elective surgeries are exceeding pre-COVID levels, indicating a positive outlook for 2024. OHI's portfolio has significantly reduced risk and has effectively restructured and transitioned multiple tenants.

Portfolio Pulse from Vandana Singh

September 08, 2023 | 6:20 pm